Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomes

Background: Lung adenocarcinoma (LUAD) is characterized by low overall survival rates. This research aims to explore the association between long non-coding RNAs (lncRNAs) and chromatin histone methylation/demethylation modifiers in LUAD. Methods: Datasets from The Cancer Genome Atlas (TCGA), Molecu...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Xiao Zhu, Zhuolong Xiong
Materialtyp: Artikel
Språk:engelska
Publicerad: Elsevier 2025-08-01
Serie:Medicine in Omics
Ämnen:
Länkar:http://www.sciencedirect.com/science/article/pii/S2590124925000057
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!
_version_ 1839630851674996736
author Xiao Zhu
Zhuolong Xiong
author_facet Xiao Zhu
Zhuolong Xiong
author_sort Xiao Zhu
collection DOAJ
description Background: Lung adenocarcinoma (LUAD) is characterized by low overall survival rates. This research aims to explore the association between long non-coding RNAs (lncRNAs) and chromatin histone methylation/demethylation modifiers in LUAD. Methods: Datasets from The Cancer Genome Atlas (TCGA), Molecular Signatures Database (MSigDB), and IEU Open genome-wide association studies (GWAS) database were analyzed. A prognostic risk model for LUAD was developed based on 32 lncRNAs linked to histone modification. The relationship between lncRNAs and the high-risk group of lung cancer was evaluated, and GO/KEGG analysis was conducted to investigate the connection between chromatin histone modification-related lncRNAs and biological processes/pathways. Mendelian Randomization methods, including Inverse Variance Weighted (IVW) and Bayesian Weighted Mendelian Randomization (BWMR), were employed to validate the GO/KEGG results. MR-Egger intercept test, Cochran’s Q test, and leave-one-out Analysis were utilized to assess the sensitivity of Mendelian Randomization analysis. Tumor mutation burden (TMB) analysis was performed to evaluate the prognostic impact of high-risk patients with high TMB. Results: Identified lncRNAs, including AC025741.1 and NHS-AS1, demonstrated strong associations with the high-risk group. GO/KEGG analysis revealed significant correlations between chromatin histone modification-related lncRNAs and microtubule-based movement and cytochrome enzyme P450. Response to the renin-angiotensin agents is a protective factor for lung cancer, while response to glucocorticoids is a risk factor for lung cancer. Immunomarkers MDSC, CAF, and Exclusion showed positive correlations with the risk score, and the combined effects of CAF and MDSC were found to play a pivotal role in LUAD development and progression. Conclusion: Our study not only establishes a promising LUAD prognostic risk model with potential implications for immunotherapy but also identifies lncRNAs as immune markers for LUAD immunotherapy. Additionally, we validate the causal relationship between chromatin histone methylation-related pathways and lung cancer, bolstering our understanding from a genetic perspective and opening avenues for targeted interventions in LUAD treatment.
format Article
id doaj-art-e7c58b0e203149faa99fe58b4a9fbbe3
institution Matheson Library
issn 2590-1249
language English
publishDate 2025-08-01
publisher Elsevier
record_format Article
series Medicine in Omics
spelling doaj-art-e7c58b0e203149faa99fe58b4a9fbbe32025-07-13T04:54:54ZengElsevierMedicine in Omics2590-12492025-08-0114100045Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomesXiao Zhu0Zhuolong Xiong1The Second Affiliated Hospital of Guangdong Medical University, Guangdong Medical University, Zhanjiang, ChinaDepartment of Orthopedics, The First Affiliated Hospital of Jinan University, Guangzhou, China; Corresponding author at: Department of Orthopedics, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.Background: Lung adenocarcinoma (LUAD) is characterized by low overall survival rates. This research aims to explore the association between long non-coding RNAs (lncRNAs) and chromatin histone methylation/demethylation modifiers in LUAD. Methods: Datasets from The Cancer Genome Atlas (TCGA), Molecular Signatures Database (MSigDB), and IEU Open genome-wide association studies (GWAS) database were analyzed. A prognostic risk model for LUAD was developed based on 32 lncRNAs linked to histone modification. The relationship between lncRNAs and the high-risk group of lung cancer was evaluated, and GO/KEGG analysis was conducted to investigate the connection between chromatin histone modification-related lncRNAs and biological processes/pathways. Mendelian Randomization methods, including Inverse Variance Weighted (IVW) and Bayesian Weighted Mendelian Randomization (BWMR), were employed to validate the GO/KEGG results. MR-Egger intercept test, Cochran’s Q test, and leave-one-out Analysis were utilized to assess the sensitivity of Mendelian Randomization analysis. Tumor mutation burden (TMB) analysis was performed to evaluate the prognostic impact of high-risk patients with high TMB. Results: Identified lncRNAs, including AC025741.1 and NHS-AS1, demonstrated strong associations with the high-risk group. GO/KEGG analysis revealed significant correlations between chromatin histone modification-related lncRNAs and microtubule-based movement and cytochrome enzyme P450. Response to the renin-angiotensin agents is a protective factor for lung cancer, while response to glucocorticoids is a risk factor for lung cancer. Immunomarkers MDSC, CAF, and Exclusion showed positive correlations with the risk score, and the combined effects of CAF and MDSC were found to play a pivotal role in LUAD development and progression. Conclusion: Our study not only establishes a promising LUAD prognostic risk model with potential implications for immunotherapy but also identifies lncRNAs as immune markers for LUAD immunotherapy. Additionally, we validate the causal relationship between chromatin histone methylation-related pathways and lung cancer, bolstering our understanding from a genetic perspective and opening avenues for targeted interventions in LUAD treatment.http://www.sciencedirect.com/science/article/pii/S2590124925000057Lung adenocarcinomaGWASHistone methylationHistone demethylationMendelian randomization
spellingShingle Xiao Zhu
Zhuolong Xiong
Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomes
Medicine in Omics
Lung adenocarcinoma
GWAS
Histone methylation
Histone demethylation
Mendelian randomization
title Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomes
title_full Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomes
title_fullStr Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomes
title_full_unstemmed Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomes
title_short Multi-omics integration reveals chromatin-associated lncRNA prognostic model in lung adenocarcinoma: Bridging GWAS, transcriptome and clinical outcomes
title_sort multi omics integration reveals chromatin associated lncrna prognostic model in lung adenocarcinoma bridging gwas transcriptome and clinical outcomes
topic Lung adenocarcinoma
GWAS
Histone methylation
Histone demethylation
Mendelian randomization
url http://www.sciencedirect.com/science/article/pii/S2590124925000057
work_keys_str_mv AT xiaozhu multiomicsintegrationrevealschromatinassociatedlncrnaprognosticmodelinlungadenocarcinomabridginggwastranscriptomeandclinicaloutcomes
AT zhuolongxiong multiomicsintegrationrevealschromatinassociatedlncrnaprognosticmodelinlungadenocarcinomabridginggwastranscriptomeandclinicaloutcomes